美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Reviva Pharmaceuticals Holdings, Inc. Warrant 2025/12/25 11.5C

0.0596

-0.0001-0.17%

成交量：1.76万

成交额：1,023.59

市值：- -

市盈率：- -

高：0.0650

开：0.0600

低：0.0528

收：0.0597

数据加载中...

总览公司新闻公告

公司资料

公司名字：

Reviva Pharmaceuticals Holdings, Inc. Warrant 2025/12/25 11.5C

交易所：

NASDAQ

成立时间：

- -

员工人数：

- -

公司地址：

- -

官网：

http://www.revivapharma.com

邮编：

- -

电话：

- -

传真：

- -

简介：

Reviva Pharmaceuticals Holdings, Inc.于2018年3月20日在英属维尔京群岛注册成立。Reviva是一家临床阶段制药公司，致力于解决中枢神经系统、心血管、代谢和炎症疾病领域未满足的医疗需求。Reviva的主要重点是开发其领先候选产品RP5063 (brilaroxazine)，用于精神分裂症、双向情感障碍和重度抑郁症的治疗。Reviva还打算开发用于治疗PAH和IPF的RP5063。RP5063是一种血清素、多巴胺和烟碱受体活性化合物，目前正在临床开发中。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/RVPHW/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RVPHW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RVPHW\",,,,,undefined,":{"symbol":"RVPHW","market":"US","secType":"WAR","nameCN":"Reviva Pharmaceuticals Holdings, Inc. Warrant 2025/12/25 11.5C","latestPrice":0.0596,"timestamp":1745955580666,"preClose":0.0597,"halted":0,"volume":17621,"delay":0,"strike":11.5,"lastTradingDate":1766638800000,"nameEN":"Reviva Pharmaceuticals Holdings, Inc. Warrant 2025/12/25 11.5C","floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":-0.0001,"latestTime":"04-29 15:51:48 EDT","open":0.06,"high":0.065,"low":0.0528,"amount":1023.58820731,"amplitude":0.204355,"askPrice":0.0673,"askSize":884,"bidPrice":0.0521,"bidSize":996,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1745956800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":0.0597,"preHourTrading":{"tag":"盘前","latestPrice":0.0665,"preClose":0.0597,"latestTime":"09:21 EDT","volume":9,"amount":0.6444,"timestamp":1745932896557},"postHourTrading":{"tag":"盘后","latestPrice":0.07,"preClose":0.065,"latestTime":"17:35 EDT","volume":1489,"amount":104.1998,"timestamp":1745876156670},"volumeRatio":0.479108,"lotSize":1,"type":1,"expireDate":1766638800000,"ul":"RVPH","ulStockBrief":{"symbol":"RVPH","market":"US","secType":"STK","nameCN":"Reviva Pharmaceuticals Holdings, Inc.","latestPrice":0.8513,"timestamp":1745956249917,"preClose":0.8704,"halted":0,"volume":261456,"delay":0}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RVPHW\",,,,,undefined,":{"symbol":"RVPHW","floatShares":0,"roa":"-23.19%","roe":"-53.85%","lyrEps":0,"volumeRatio":0.479108,"shares":0,"dividePrice":0,"high":0.065,"amplitude":0.204355,"preClose":0.0597,"low":0.0528,"week52Low":0.0226,"pbRate":"0.00","week52High":0.78,"institutionHeld":0,"latestPrice":0.0596,"committee":0.059574,"eps":0,"divideRate":0,"volume":17621,"delay":0,"ttmEps":0,"open":0.06,"prevYearClose":0.1644,"prevWeekClose":0.0617,"prevMonthClose":0.0549,"prevQuarterClose":0.0549,"fiveDayClose":0.0635,"twentyDayClose":0.0549,"sixtyDayClose":0.198},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.revivapharma.com","stockEarnings":[{"period":"1week","weight":0.215},{"period":"1month","weight":0.2037},{"period":"3month","weight":-0.6338},{"period":"6month","weight":-0.4323},{"period":"1year","weight":-0.8774},{"period":"ytd","weight":-0.6046}],"compareEarnings":[{"period":"1week","weight":0.0719},{"period":"1month","weight":-0.0087},{"period":"3month","weight":-0.0888},{"period":"6month","weight":-0.0503},{"period":"1year","weight":0.0838},{"period":"ytd","weight":-0.0601}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Reviva Pharmaceuticals Holdings, Inc.于2018年3月20日在英属维尔京群岛注册成立。Reviva是一家临床阶段制药公司，致力于解决中枢神经系统、心血管、代谢和炎症疾病领域未满足的医疗需求。Reviva的主要重点是开发其领先候选产品RP5063 (brilaroxazine)，用于精神分裂症、双向情感障碍和重度抑郁症的治疗。Reviva还打算开发用于治疗PAH和IPF的RP5063。RP5063是一种血清素、多巴胺和烟碱受体活性化合物，目前正在临床开发中。","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.203101},{"month":2,"riseRate":0.571429,"avgChangeRate":-0.00832},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.216573},{"month":4,"riseRate":0.571429,"avgChangeRate":0.114915},{"month":5,"riseRate":0.5,"avgChangeRate":0.198451},{"month":6,"riseRate":0.5,"avgChangeRate":0.202005},{"month":7,"riseRate":0,"avgChangeRate":-0.255197},{"month":8,"riseRate":0.5,"avgChangeRate":0.167803},{"month":9,"riseRate":0.833333,"avgChangeRate":0.11375},{"month":10,"riseRate":0.166667,"avgChangeRate":0.205487},{"month":11,"riseRate":0.571429,"avgChangeRate":0.33309},{"month":12,"riseRate":0.571429,"avgChangeRate":0.087235}],"exchange":"NASDAQ","name":"Reviva Pharmaceuticals Holdings, Inc. Warrant 2025/12/25 11.5C","nameEN":"Reviva Pharmaceuticals Holdings, Inc. Warrant 2025/12/25 11.5C"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"RVPHW\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RVPHW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RVPHW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RVPHW\",market:\"US\",delay:false,,,undefined,":{}}}